EUVIMEDEUVIMED entdecken
Vergleichsstudie

A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?

Salvatore Docimo iD, Jay Shah, Gus Warren, Samer Ganam, Joseph Sujka, Christopher DuCoin

Surgical Endoscopy · 2024-11 · 38 (11) · 6560-6565

DOI: 10.1007/s00464-024-11191-1 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Surgical Endoscopy, online erschienen am 16.09.2024. Verfasst von Salvatore Docimo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Tampa General Hospital, Horatio Street, Tampa, FL, 33609, USA. docimo@usf.edu. Hauptthemen laut MEDLINE: Bariatric Surgery, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: With the prevalence of obesity rising in the US, medical management is of increasing importance. Two popular options for the treatment of obesity are bariatric surgery (e.g. sleeve gastrectomy and Roux-en-Y gastric bypass) and the increasingly popular GLP-1 Receptor Agonists (GLP-1 s). This study examines the initial and long-term costs of GLP-1 s compared to bariatric surgery. STUDY DESIGN: We compared average 2023 national retail prices for GLP-1 s to surgical cost estimates from 2015 adjusted for inflation. We then plotted the cumulative medication cost over time against the flat cost of each surgery, thus calculating "break-even points" (when medication costs equal surgery costs). The findings revealed a crucial insight, for some GLP-1 s like Saxenda and Wegovy, the high cost of ongoing use surpasses the cost of RYGB in less than a year and sleeve gastrectomy within nine months. Even the most affordable option, Byetta, becomes costlier than surgery after around 1.5 years. RESULTS: This highlights the importance of looking beyond the initial financial investment when considering cost-effectiveness. Additionally, while not directly assessed, this study acknowledges that GLP-1 s take time to reach full effectiveness, potentially delaying weight loss while accumulating costs. Concerns also exist about weight regain after discontinuing the medication. CONCLUSION: This study is limited by the real-world variation for individual treatment costs (e.g. insurance), a limited evaluation of long-term costs associated with either treatment modality and their co-morbidities, and the reality of patient preference providing subjective value to either modality. Overall, the study offers insights into the financial trade-offs between GLP-1 s and bariatric surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryGlucagon-Like Peptide-1 Receptor AgonistsHumansCost-Benefit AnalysisObesity, MorbidUnited StatesDrug CostsObesityGastrectomy

Stichwörter der Autor:innen

Bariatric surgeryCost effectivenessDiabetesGLP-1 receptor agonistMounjaroObesityOzempicRoux-en-Y gastric bypassSleeve gastrectomyWegovy

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Gastrointestinal Surgery, Tampa General Hospital, Horatio Street, Tampa, FL, 33609, USA. docimo@usf.edu.
  • Morsani College of Medicine, University of South Florida, Horatio Street, Tampa, FL, 33609, USA.
  • Division of Gastrointestinal Surgery, Tampa General Hospital, Horatio Street, Tampa, FL, 33609, USA.

ORCID-Profile: Salvatore Docimo

Zitieren

APA

Docimo, S., Shah, J., Warren, G., Ganam, S., Sujka, J., & DuCoin, C. (2024). A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?. Surgical Endoscopy, 38(11), 6560-6565. https://doi.org/10.1007/s00464-024-11191-1

Vancouver

Docimo S, Shah J, Warren G, Ganam S, Sujka J, DuCoin C. A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?. Surgical Endoscopy. 2024;38(11):6560-6565. doi:10.1007/s00464-024-11191-1

BibTeX
@article{Docimo2024,
  author = {Docimo, Salvatore and Shah, Jay and Warren, Gus and Ganam, Samer and Sujka, Joseph and DuCoin, Christopher},
  title = {A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?},
  journal = {Surgical Endoscopy},
  year = {2024},
  volume = {38},
  number = {11},
  pages = {6560--6565},
  doi = {10.1007/s00464-024-11191-1}
}
Kostenlos starten →